| 2026-08-20 | Press release | Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference |
| 2026-08-10 | Press release | Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates |
| 2026-06-29 | Press release | Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes |
| 2026-06-04 | Presentation | June 2026 Corporate Presentation |
| 2026-06-02 | Press release | Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-19 | Press release | Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference |
| 2026-05-12 | Press release | Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates |
| 2026-05-06 | Press release | Press release |
| 2026-05-06 | Press release | Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement |
| 2026-05-06 | Press release | Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement |
| 2026-04-30 | Press release | FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy |
| 2026-04-23 | Press release | Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026 |
| 2026-03-24 | Presentation | THT 2026 AVIM Therapy Presentation |
| 2026-03-24 | Presentation | CRT 2026 AVIM Therapy Presentation |
| 2026-03-12 | Press release | Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update |
| 2025-11-26 | Press release | Press release |
| 2025-11-10 | Press release | Press release |
| 2025-11-03 | Press release | Press release |
| 2025-10-28 | Press release | Press release |
| 2025-02-12 | Presentation | THT 2025 Presentation |
| 2024-12-09 | Press release | Press release |
| 2024-11-12 | Press release | Press release |
| 2024-07-30 | Press release | Press release |
| 2023-09-19 | Press release | Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hy |
| 2023-08-08 | Press release | Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Pati |
| 2022-09-20 | Press release | Orchestra BioMed™ Announces Presentation of Positive Long-Term Clinical Results from MODERATO II Control Patients Crosso |
| 2022-07-05 | Press release | Orchestra BioMed™ Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans to List |
| 2021-11-05 | Press release | Orchestra BioMed™ Announces Presentations at TCT 2021 of Positive Long-Term Clinical Results from the MODERATO II Study |
| 2021-08-17 | Press release | Orchestra BioMed™ Announces Peer-Reviewed Publication of MODERATO II Study Results Showing a Statistically Significant R |
| 2021-07-30 | Press release | Orchestra BioMed™ Announces Clinical Data Demonstrating a Significant and Sustained Reduction in Blood Pressure in MODER |
| 2021-05-17 | Press release | Orchestra BioMed™ Announces Clinical Data Showing Significant and Sustained Reduction in Systolic Blood Pressure Out to |
| Press release | Orchestra BioMed™ Enhances Management Team with Appointment of Regulatory Affairs and Combination Product Expert Bob Lau |
| Presentation | Daniel Burkhoff, MD, PhD, presented data from our MODERATO II double-blind, randomized study of BackBeat Cardiac Neuromo |
| Press release | Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027 |